Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
An evaluation of risperidone drug interactions
Autore:
DeVane, CL; Nemeroff, CB;
Indirizzi:
Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA Med Univ S Carolina Charleston SC USA 29425 Sci, Charleston, SC 29425 USA Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA Emory Univ Atlanta GA USA ed, Dept Psychiat & Behav Sci, Atlanta, GA USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 4, volume: 21, anno: 2001,
pagine: 408 - 416
SICI:
0271-0749(200108)21:4<408:AEORDI>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; CYTOCHROMES P450 2D6; SCHIZOPHRENIC-PATIENTS; PSYCHIATRIC-PATIENTS; BIPOLAR DISORDER; PROTEIN-BINDING; PHARMACOKINETICS; METABOLISM; AUGMENTATION; CLOZAPINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
54
Recensione:
Indirizzi per estratti:
Indirizzo: DeVane, CL Med Univ S Carolina, Dept Psychiat, 67 President St, Charleston, SC 29425 USA Med Univ S Carolina 67 President St Charleston SC USA 29425 USA
Citazione:
C.L. DeVane e C.B. Nemeroff, "An evaluation of risperidone drug interactions", J CL PSYCH, 21(4), 2001, pp. 408-416

Abstract

Risperidone, an atypical antipsychotic drug, is widely used in the treatment of psychoses associated with schizophrenia, Alzheimer's disease, and other psychiatric disorders. Polypharmacology is a necessary condition for theoptimal treatment of many patients with comorbid psychiatric and medical illness. One concern raised by the widespread use of multiple concurrent pharmacotherapies is the potential for drug-drug interactions to adversely affect patient outcome. Accordingly, the biomedical Literature was reviewed for reports of drug interactions involving risperidone, and the clinical significance of each report was evaluated. Additionally, the potential for risperidone to participate in drug interactions was evaluated by considering the drug's pharmacokinetic properties. Controlled studies and case reports indicate that risperidone has a low potential for metabolic drug interactions. Drugs that inhibit cytochrome P450 (CYP) 2D6 or induce or inhibit CYP3A4 may alter risperidone plasma concentrations, but the clinical significance of such interactions seems to be minimal. Adherence to a few guidelines forthe design of dosage regimens should Limit the effect of drug-drug interactions on patient status and contribute to optimal pharmacotherapy with risperidone.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/12/19 alle ore 11:49:51